






















![]()
Q1: 2026-04-30 Earnings Summary
EPS of $0.21 beats by $0.46
|
Revenue of
$156.10M
(-29.75% Y/Y)
beats by $11.10M
Emergent BioSolutions Inc. (EBS) Q1 2026 Earnings Call April 30, 2026 5:00 PM EDT
Company Participants
Frank Vargo
Joseph Papa - CEO, President & Director
Richard Lindahl - Executive VP & CFO
Conference Call Participants
Jessica Fye - JPMorgan Chase & Co, Research Division
Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division
Rishi Parekh
Alex Kelsey
Presentation
Operator
Good day and thank you for standing by. Welcome to the Q1 2026 Emergent BioSolutions Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Frank Vargo, Vice President, Treasurer.
Frank Vargo
Good afternoon, everyone, and thank you for joining us as Emergent discusses its operational and financial results for the first quarter of 2026. As is customary, today's call is open to all participants. It's being recorded and is copyrighted by Emergent BioSolutions. In addition to today's press release, a slide presentation accompanying this webcast is available to all webcast participants.
Turning to Slide 2. During today's call, Emergent may make projections and other forward-looking statements related to its business, future events, prospects or future performance. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events.
Any forward-looking statements speak only as of the date of this conference call, and except as required by law, Emergent does not undertake to update any forward-looking statements to reflect new information, events or circumstances. Investors should consider this cautionary statement as well as the risk factors identified in Emergent's periodic reports filed with the SEC when evaluating these forward-looking statements.
During today's call, Emergent may also discuss certain non-GAAP financial measures that include adjustments to GAAP figures to provide additional transparency regarding the company's operating performance. Please refer to the tables included in
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。